Enstilar Alternatives Compared
Enstilar | Otezla | Remicade |
|
---|
Enstilar (betamethasone / calcipotriene) | Otezla (apremilast) | Remicade (infliximab) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Plaque Psoriasis, Psoriasis. Enstilar may also be used for purposes not listed in this medication guide. |
Prescription only
Otezla is a PDE4 inhibitor that may be used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease. It has been associated with severe diarrhea, nausea, and v... View more |
Prescription only
Prescribed for Crohn's Disease - Active, Ankylosing Spondylitis, Inflammatory Bowel Disease, Crohn's Disease, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative... View more |
||||||||||||||||||||||||
More about Enstilar (betamethasone / calcipotriene) | More about Otezla (apremilast) | More about Remicade (infliximab) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Enstilar has an average rating of 6.7 out of 10 from a total of 71 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 28% reported a negative effect. |
Otezla has an average rating of 5.1 out of 10 from a total of 431 ratings on Drugs.com. 35% of reviewers reported a positive effect, while 41% reported a negative effect. |
Remicade has an average rating of 7.1 out of 10 from a total of 208 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: Enstilar side effects in more detail. |
See also: Otezla side effects in more detail. |
See also: Remicade side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
N/A |
||||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Enstilar prices |
View all Otezla prices |
View all Remicade prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Other betamethasone / calcipotriene brands include: Dovobet, Taclonex, Taclonex Scalp, Wynzora |
N/A |
Other infliximab brands include: Avsola, Inflectra, Ixifi, Renflexis, Zymfentra | ||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
N/A |
9 hours |
228 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 107 drugs are known to interact with Enstilar:
|
A total of 86 drugs are known to interact with Otezla:
|
A total of 498 drugs are known to interact with Remicade:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
October 16, 2015 |
March 21, 2014 |
August 24, 1998 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
|||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.